MELISSA FLOYD: Open Payments
NPI 1982248571 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$729 in 41 payments from 8 companies in 2025. Trend: 2023 $457 · 2024 $337 · 2025 $729
Food & beverage: $729
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $272 |
| AstraZeneca Pharmaceuticals LP | 6 | $150 |
| Lilly USA, LLC | 6 | $108 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $78 |
| Astellas Pharma US Inc | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Amgen Inc. | 1 | $15 |
Products named: VRAYLAR, BREZTRI, MOUNJARO, CAPLYTA, Veozah, LINZESS, QULIPTA, UBRELVY.
Industry payments across LA — which companies pay providers there.
